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Background 
The clinical utility of pretest probability models in the diagnosis of VTE has been 
well validated (1).  However, research into VTE predictability models is inadequate 
(2), especially in the aftermath of acute stroke, when development of clot in leg veins 
can be as early as  48 hours and early in the second week (3, 4).  The impact of 
improved and organised specialist stroke intervention, including thrombolytic therapy 
on clinical outcome is well known (5-7).  However, the effects of this specialist input, 
thrombolytic therapy in ischaemic stroke, and thromboprophylaxis on incidence of 
VTE in the era of hyperacute stroke care is yet unknown.  In previous studies, the 
incidence of symptomatic VTE is 1-20% (8, 9), with subclinical incidence of 8-75% 
(10-12).  There remains lack of clarity in International guidelines on timing of 
thromboprophylaxis  (13-16).  Thus a VTE prediction model to identify those at high 
risk who will benefit from early thromboprophylaxis is desirable.   We postulate that 
in the aftermath of acute stroke, and independent of the clinical intervention approach 
to the overall stroke care, markers of haemostatic activation due to endothelial 
perturbation and/or stroke severity may  predict those at risk of developing DVT.  We 
investigate the role of  laboratory factors  (thrombin generation, D-dimer, fibrinogen) 
alongside clinical factors (National Institute of Health Stroke Scale and Barthel Index) 
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in improving pretest probability. NIHSS is a measure of stroke severity and Barthel 
index is a measure of functional abilities. Thrombin generation is a novel global 
coagulation assay which has been used in non stroke patients as a research tool to risk 
stratify for recurrent VTE (17, 18), and in the diagnosis of first DVT (19-21).  
 
Methods 
 
Study objectives 
1. To predict DVT after acute stroke using markers of haemostatic activation and 
stroke severity scores. 
2. To define incidence of DVT in the era of hyperacute stroke care.  
3. To design a pretest probability model to identify patients at high risk of DVT 
 
Study design 
Participants were prospectively recruited from consecutive in-patient stroke 
admissions at King’s College Hospital NHS Foundation Trust, between June 2009 
and August 2011.  Participants with an objective diagnosis of stroke were invited to 
take part within 48 hours of admission.  Patients with radiological diagnosis of stroke 
after 48 hours or those on end of life care within 48 hours of admission and life 
expectancy less than 7 days were excluded.  Other reasons for exclusion were early 
repatriation to local hospitals, refusal to continue with study after screening, previous 
DVT/PE, previous diagnosis of cancer, prior anticoagulant therapy, and previous 
lower limb amputation.  All participants had baseline NIHSS, BI recorded. The height 
(m) and weight (kg) of all participants were measured to allow calculation of body 
mass index (BMI). Past medical history, including past cardiovascular, 
cerebrovascular history, and medication history were recorded. All patients were 
screened for DVT in week 2 using compression Doppler ultrasound scan, as described 
below.  If there was clinical suspicion of PE participants were investigated with CT 
pulmonary angiogram.  All patients with diagnosis of ischaemic stroke received 
Aspirin 75mg once daily and Dipyridamole MR 200mg twice daily within 24 hours of 
admission. And considering there was no concensus on routine thromboprophylaxis. 
This was commenced after compression ultrasound scan in week 2 if no DVT was 
found. Otherwise patients with objective evidence of DVT were treated with bridging 
therapy of clexane and warfarin. 
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The study was approved by York Research Ethics Committee (REC reference 
number: 09/H1311/12), and the local Research and Development department at 
King’s College Hospital, London.  All patients gave informed written consent prior to 
data and sample collection. 
 
Sample collection and plasma preparation 
 
Upon enrolment in the study, venous blood was collected from the antecubital vein, 
via Butterfly-21 needle (Hospira Inc, IL, USA), with minimal venous stasis using a 10 
ml syringe. Blood was immediately dispensed into 0.109M sodium citrate plastic (BD 
vacutainer, Plymouth, UK, nine parts blood to one part sodium citrate) following an 
initial 10 ml blood drawn which was subsequently added 0.369M 
ethylenediaminetetraacetic acid (EDTA) BD vacutainer (BD Diagnostics, Plymouth, 
UK).  The same blood sample collection technique was carried out between days 7-
10. 
Platelet poor plasma (PPP) for thrombin generation was prepared by centrifugation of 
blood sample in the sodium citrate plastic vacutainer using Hettich Rotina 420R 
centrifuge (Hettich, Tuttlingen, Germany) at 4750g for 10 minutes, at room 
temperature.  After the initial centrifugation, the top three-quarters of supernatant was 
decanted into a polypropylene tube and then centrifuged a second time at 4750g for 
10 minutes again at room temperature.  The top three-quarter of the supernatant was 
transferred into a plastic tube, and stored at -40oC.  Samples were processed and 
frozen within 60 minutes of collection.  
Plasma for D-dimer and Clauss fibrinogen was prepared by single centrifugation at 
3040g for 7 minutes and tested within 4 hours.  
Thrombin generation was undertaken within 12 weeks of sample collection, following 
further centrifugation after plasma thawing at 4750g for 10 minutes.  Intra-assay and 
inter-assay variability was < 5% and <12% respectively for all thrombin generation 
parameters. 
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Laboratory assays 
Thrombin generation 
Thrombin generation was measured in platelet poor plasma (PPP) with the 
ThrombinoscopeTM assay (Thrombinoscope BV, Maastrichts, Netherlands) as 
previously described (22, 23).  Final tissue factor concentration was 5pM with 4µM of 
phospholipids.  Parameters measured were lag time (minutes), time to peak (ttP, 
minutes), peak thrombin generation (nM) and endogenous thrombin potential (ETP), 
which is the area under the curve (nM.min). 
 
Standard coagulation assay  
D-dimer was measured by a latex photometric immuno-assay  and Clauss fibrinogen 
using Diagnostica Stago reagents (Asnieres, France) on the automated  STA® 
Evolution analyser(Diagnostica Stago) as described previously (24).  
Duplex  compression ultrasound scan    
All participants had bilateral whole leg duplex compression ultrasound scan 
performed in week 2 (7-10 days), by a trained Vascular Scientist.  The ultrasound 
devices used were Siemens Acuson Sequoia 512 (Erlangen, Germany) and Philips 
Healthcare iU22 (Eindhoven, The Netherlands) with a linear 3-6 MHz transducer.  
Lack of compressibility of a deep venous segment indicated the presence of DVT. 
Participants with diagnosis of DVT received therapeutic low molecular weight 
heparin or unfractionated heparin infusion in the presence of a contraindication to the 
former.  
 
Statistical analysis 
Continuous variables were given mean and standard deviation, or median and 
interquartile ranges for normal and non-normal data respectively. Categorical 
variables are presented as number and percentage.  Comparisons were made between 
groups (with/without DVT) using the unpaired t-test for normally distributed 
continuous variables. Unpaired t-test was also used to find the mean difference 
between the 2-point coagulation assays.  The Mann-Whitney test was used for non-
normally distributed continuous variables.  Fisher’s exact test was used to compare 
categorical variables between those with and without DVT.  Where applicable, odd 
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ratios were obtained from logistic regression in an adjusted and unadjusted analysis as 
a measure of association between variables tested and DVT.  Subsequently, the joint 
effect of the variables upon development of DVT was evaluated using multivariable  
logistic regression analysis. To limit the number of variables in this analysis, only 
factors with a p ≤0.2 from univariable analysis were included in this analysis.  A 
backward selection procedure was used to retain only the statistically significant 
variable.   Adjustments were made for the effect of cofounder factors (age, body mass 
index, Barthel index, NIHSS) on the statistically significant variables.  Distribution of 
D-dimer was positively skewed and multimodal and as such underwent logarithm  
transformation to facilitate normal distribution  and dichotomisation.  We adjusted for 
the missing data from the observed data, by replacing missing values with predicted 
scores from the regression equation. This was done by single imputation.  Further 
analysis was performed with receiver operating characteristic (ROC) curves, to 
determine the area under the ROC curve (AUC), which was used to identify the 
optimum cut-point.  The optimum cut-point was the point which maximised the 
combination of sensitivity and specificity. Statistical significance was given a p-value 
of <0.05.  All statistical analysis were performed using Stata version 12 software 
(Stata Corp LP, Texas, USA). 
 
Results 
 
Participant demographics and risk factors 
Five hundred participants were screened, with exclusions as shown in the Study 
algorithm in figure 1.  
188 participants gave consent and were recruited into the study.  From this number, 
96 participants withdrew due to early repatriation to local hospitals, medical 
complications such as severe septicaemia, bleeding diastheses, renal failure requiring 
frequent dialysis, upper gastrointestinal bleeding requiring intensive therapy unit 
admissions, New York Heart Association class IV heart failure and acute severe 
myocardial infarction.  These participants were moribund and were as a result unfit 
for further investigations including Doppler ultrasound scan. The remaining  
participants (n=92) had complete investigations. Of these numbers, there were 9 
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haemorrhagic, and 83 ischaemic strokes.  18/92 participants had asymptomatic DVT 
diagnosed in the second week, of which 3 were in the haemorrhagic and 15 in  
ischaemic stroke.  There were in total 4 proximal and 14 distal DVT. Of the patients 
with DVT, 6 had received intravenous recombinant tissue plasminogen activator (r-
tPA) for ischaemic stroke.   
Table 1, showed demographic details in those with and without DVT.  There were no 
significant differences in age and gender distribution. With regard to the risk factors, 
diabetes was over represented in DVT patients and hypertension in those without 
DVT. BMI in those with DVT was higher than those without (28.6±4.6 versus 
26.1±4.9; p=0.05).  No other risk factors for stroke were associated with  DVT. Of the 
total patients investigated (n=92), 29 patients were treated with intravenous r-tPA. Of 
these  21% (6/29) went on to develop DVT,  constituting 40% (6/15) of all DVT in 
the ischaemic stroke subgroup.   
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Table 1. Demographic details and risk factors for stroke.  
IHD-Ischaemic heart disease; NIHSS-national institute of health stroke scale; BMI-body mass index; DVT- deep 
vein thrombosis. CUSS- compression ultrasound scan 
Category                                          No DVT                               DVT                                  p-value                                                                     
.                                                         n=74                                     n=18                   
Age,mean (SD)                                 68.9 ± 14.8                          69.7 ± 13.4                     0.83            
Male, n (%)                                      35 (47)                                 9(50)                              0.84     
Ethnicity 
 African-Caribbean, n (%)                 29 (39)                                6 (33)                              0.18 
White, n (%)                                      45 (61)                               12 (67)                             0.23 
Risk factors 
Diabetes Mellitus, n(%)                    14(19)                                 8(44)                               0.02 
Hypertension, n (%)                          44(60)                                 6(33)                               0.03 
Smoking, n (%)                                 11(15)                                 4(22)                               0.20 
Atrial fibrillation, n (%)                    13(18)                                 4(22)                               0.22 
Dyslipidaemia, n (%)                        24(32)                                 3(17)                               0.10 
IHD, n (%)                                        6(8)                                     3(17)                               0.19 
Peripheral vascular disease, n (%)    4(5)                                     1(6)                                 0.42                 
BMI- mean (SD)                               26.1± 4.9                             28.6±4.6                         0.05   
Stroke severity 
NIHSS- mean (SD)                           12.1± 7.1                            15.6±7.7                          0.07   
NIHSS <7, n (%)                               24(32)                                4 (22)                                   - 
NIHSS 8-14, n (%)                           15 (19)                                3 (17)                                   - 
 NIHSS > 14, n (%)                          35 (47)                                11 (61)                                 - 
Motor limb weakness 
Paresis, n (%)                                    53(72)                                 17(94)                             0.03 
Functional rating 
Barthel index- mean(SD)                  9.4±6.1                               6.1±6.5                            0.05 
Barthel  index < 9, n (%)                  43(58)                                 13 (72)                                 - 
Barthel  index > 9, n (%)                  31 (42)                                 5 (28)                                  - 
Prestroke  medications 
Antiplatelets, n (%)                           8(11)                                   2(11)                               0.32 
Statins, n (%)                                    13 (18)                                 3(17)                               0.27 
Antihypertensive, n (%)                   12(16)                                  4(22)                               0.24 
VTE prophylaxis 
GCS, n (%)                                        2 (2.7)                                1(5.6)                                   - 
IPC, n (%)                                          -                                             -                                       - 
Enoxaparin, n (%)                             1(1.4)                                     -                                        - 
Unfractionated heparin, (%)               -                                             -                                        - 
Time to acquisition of tested variables (All participants) 
NIHSS, median (IQR), min                             28 (17,42)                                             
Barthel index, median (IQR), min                   47 (17,6)                                             
NCCT, median (IQR), hours                           3.8 (0.5, 23)                                          
Coagulation markers, median (IQR) hours     17 (10, 33)                                            
DtN time (rtPA), median (IQR), hours            47 (34, 84)                                          
CUSS, median (IQR), days                              8.9 (7.2, 10.8) 
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Relationship between clinical factors and DVT 
Participants with DVT had worse stroke severity as indicated by higher NIHSS 
(15.6±7.7 versus 12.1±7.1; p=0.07), and when compared to the non DVT group, more 
patients in the DVT group had NIHSS greater than 14 (61% versus 47%), as shown in 
Table 1. There was significantly more motor limb weakness in the DVT group (94% 
versus 72%; p=0.03).  Patients in the DVT group were functionally less able with 
lower BI  group (6.1±6.5 versus 9.4±6.1; p=0.05), BMI in those with DVT was higher 
than those without (28.6±4.6 versus 26.1±4.9; p=0.05). There were 18 DVTs 
identified, out of which 6 were proximal, and 12 distal. In proximal DVT, 1 
participant had bilateral DVT.  
Relationship between thrombin generation and DVT 
Table 2, shows thrombin generation results in patients with DVT versus those without 
DVT.   Thrombin generation parameters did not differ between the groups at baseline 
and in the second week.  
Relationship between D-dimer, fibrinogen and DVT 
At both baseline, and week 2, patients with DVT had significantly higher D-dimer 
levels, as shown in Table 2.   In the DVT group median  D-dimer  was significantly 
higher at baseline (2280ng/mL Vs 1035ng/mL, p=0.001) and in the second week  
(2240 ng/mL Vs 970 ng/mL; p<0.001).   
 
A graphical illustration of the difference in D-dimer values between the two groups is 
shown in.  Box plot in figure 2a showed the association between baseline D-dimer 
(time 1) and DVT, while box plot in figure  2b, showed the association between week 
2, (time 2) D-dimer and DVT.  There were no difference in fibrinogen levels between 
the two groups.  
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Table 2.  Laboratory predictors  of  deep vein thrombosis  
 Test                                                                  No DVT                                       DVT                                    p-value 
                                                                         (n=74)                                           (n=18)                                    
      
Thrombin generation assays 
Lag time 1, min- median (IQR)                        3.2 (2.7, 4.0)                                 3.2 (2.8, 3.6)                        0.96                 
Lag time 2, min- median (IQR)                        3.4 (2.9, 4.2)                                3.3 (3.0, 4.0)                         0.65    
Change in Lag time, min-mean (SD)               0.4 (1.3)                                        0.0 (1.2)                                0.32    
                                                    
Baseline ETP, nmol/min-mean (SD)               1730  ± 348                                   1687 ± 355                           0.66 
Week 2 ETP, nmol/min- mean (SD)                1697  ± 375                                   1671 ± 234                          0.93                 
Change  in ETP, nmol/min-mean  (SD)           -48 (416)                                       -58 (252)                              0.93   
                                            
Baseline ttP, min- median (IQR)                      6.0 (5.3, 6.6)                                 6.0(5.3, 6.8)                          0.96                   
Week 2 ttP, min- median (IQR)                        6.3 (5.3, 7.2)                                  5.7 (5.3, 6.7)                        0.22 
Change in ttP, min-mean (SD)                         0.4 (1.7)                                        -0.1 (1.2)                               0.27    
                    
Baseline Peak, nmol-mean (SD)                      36 ± 78)                                         327 ± 54                               0.66                  
Week 2 Peak, nmol- mean (SD)                       40 ± 80                                          338 ± 57                               0.92    
Change in Peak, nmol-mean (SD)                   2 (73)                                           10 (39)                                   0.66    
                        
Other coagulation assays 
Baseline D-dimer , ng/mL-median (IQR)        1035 (540, 1685)                                2280 (1590, 3940)         0.001 
Week 2 D-dimer , ng/mL- median (IQR)        970 (460, 1900)                                 2240 (1280, 3940)          0.001  
Change in D-dimer, ng/mL- mean (SD)          -130 (2150)                                       -408 (2726)                      0.65     
                                          
Baseline Fibrinogen, g/L - mean (SD)              3.9 ± 1.4                                             3.9 ± 1.4                         0.85 
Week 2 Fibrinogen, g/L- mean (SD)                 4.6 ± 1.3                                            4.5 ± 1.4                          0.73 
Change in Fibrinogen, g/L                                 0.6 (1.3)                                             0.7 (1.4)                          0.85 
 
 
 ETP- Endogenous thrombin potential,  ttP-Time to peak,  SD- Standard deviation,  IQR- Interquatile range,  DD-D-dimer 
 
The effect of clinical and laboratory factors in order of utility in predicting DVT with 
corresponding binomial confidence intervals are shown in tables 3a-d.  ROC curve for 
NIHSS (figure 3a), ROC curve for Barthel index (figure 3b), ROC curve for baseline 
D-dimer (figure 3c), ROC curve for week 2 D-dimer (figure 3d) are illustrated below.   
D-dimer values at baseline and week 2 were better predictors of DVT with areas 
under the ROC curve (AUC) of 0.75 at both time points.  Cut point at 50th centile for 
baseline (1660ng/mL) and week 2 D-dimer (1570ng/mL), gave 0.71 sensitivity (95% 
CI, 0.47-0.90) and 0.74 specificity (95% CI, 0.62-0.83) and 0.71 sensitivity (95% CI: 
0.45-0.90), specificity 0.71(95% CI, 0.60-0.82) respectively.  ROC curve analysis of 
Barthel index and NIHSS revealed they were the least predictors respectively, with  
AUC of 0.697 for Barthel index which gave 0.67  sensitivity (95% CI, 0.41-0.81) and 
0.65 specificity (95% CI, 0.53-0.76) when the cut point is set at 6 (50th centile).  The 
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AUC for NIHSS 50th centile cut-point of 14 was 0.633, which gave 0.64 sensitivity 
(95% CI, 0.41-0.87), and specificity of 0.53 (95% CI, 0.41-0.64).  
 
Table 3, Prediction of Deep vein thrombosis at 50th centile cut-points using ROC 
curves. 
Variables Cut-off Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
 
     
Baseline DD 1660ng/ml 0.71 
(0.47, 0.90) 
0.74  
(0.62, 0.83) 
0.39  
(0.22, 0.58) 
0.95 
(0.83, 0.99) 
Week  2 DD 1570ng/ml 0.71 
(0.45, 0.90) 
0.71 
(0.60, 0.82) 
0.38 
(0.21, 0.56) 
0.91  
(0.80, 0.97) 
Barthel Index   6 0.67 
(0.41, 0.81) 
0.65 
(0.53, 0.76) 
0.32 
(0.18, 0.49) 
0.89  
(0.77, 0.96) 
NIHSS 14 0.64 
(0.41, 0.87) 
0.53 
(0.41, 0.64) 
0.26 
(0.14, 0.40) 
0.87 
(0.73, 0.95) 
 
     
 
     
 
PPV, positive predictive value;. NPV, negative predictive value; NIHSS, national institute of health stroke scale; 
BI, barthel index; CI, confidence interval; DD, D-dimer 
 
A multivariate logistic regression analysis was performed to jointly examine the 
association between factors tested and DVT, and a backward selection procedure was 
used to retain only statistically significant variable.  Baseline D-dimer was the only 
significant variable after this analysis, with crude OR of  8.11 (95% CI: 1.90-34.7; 
p=0.005) for DVT as shown in table 4.  Logarithm of  baseline D-dimer was then 
undertaken, where  a 10-fold increase in D-dimer which is equivalent to a 1-unit 
increase on the log scale is associated with odds of DVT, and this increased 
predictability by a factor of 8.  In figure 4, is a graphical illustration showing a fitted 
relationship of the probability of DVT at different baseline D-dimer values.  
Considering that Baseline D-dimer showed a multimodal distribution, 
dichotomisation was undertaken at median (1500ng/mL), 75th centile (4940ng/mL) 
and 90th centile (7600ng/mL) for the purpose of analysis.  D-dimer showed a dose 
dependent trend towards association with DVT before adjustment for cofounders.  D-
dimer greater than 1500ng/ml was associated OR 4.10 (95% CI, 1.39-7.40; p=0.006) 
with increased odds of DVT.  While D-dimer above the 75th and 90th percentile was 
associated with an OR 5.82 (95% CI, 1.72-8.40; p=0.003) and 6.91 (95% CI, 1.84-
10.2; p=0.005) odds of  DVT respectively.  After adjustment for cofounders (age, 
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BMI, BI, NIHSS), D-dimer above the median showed significant association OR 
2.95(95% CI 1.98-5.60; p=0.04). The  adjusted OR for D-dimer above 75th and 90th 
centiles also remained significant at 3.89 (95% CI 2.10-9.80; p=0.002) and 3.4 (95% 
CI:1.17-11.4; p=0.003) respectively. 
D-dimer measured in week 2 (DD2) was analysed as a continous variable after log 
transformation and after dichotomisation at the upperlimit of normal which was taken 
as 500ng/mL, revealed the unadjusted OR for log of DD2 4.32 (95% CI: 1.23- 14.3; 
p=0.003) for DVT.  After adjustment for cofounders log of DD2 was 3.9 (95% CI 
1.91-7.93; p=0.20).  At week 2, a positive D-dimer was also associated with DVT 
with OR of 5.3 (95% CI 1.8-13.9; p=0.004). A summary of final model of the 
multivariable logistic regression analysis and predictors of DVT in unadjusted and 
adjusted analysis is table 4 below. 
 
  Table 4. Unadjusted and adjusted odds of association of predictors of DVT 
Outcome                 Unadjusted OR (95% CI)       p-value        Adjusted OR (95% CI)    p-value.                                                                   
Age*                        3.11(1.70-4.10)                         0.02                   1.89 (0.67-6.69)               0.20† 
BMI**                     4.90 (1.87-6.66)                        0.05                   3.20 (1.97-4.89)              0.06† 
Barthel index***    5.1 (2.67-8.90)                           0.08                   4.2 (1.76- 8.40)               0.15† 
NIHSS****            3.6 (1.03-9.11)                          0.07                    2.81 (0.73-8.33)              0.19† 
 DD1 ≥(Crude)        8.11 (1.90, 34.7)                        0.005                              - 
DD1 ≥1500ng/mL   4.10 (1.39-7.40)                        0.006                  2.95 (1.98-5.60)              0.005† 
(median) 
DD1 ≥4940ng/mL     5.82 (1.72-8.40)                      0.003                  3.98 (2.10-9.80)              0.005† 
(75th centile) 
 
DD1 ≥7600ng/mL     6.91 (1.84-10.2)                        0.005              3.4 (1.17-11.4)                 0.003† 
(90th centile) 
Log DD2                    4.32 (1.23-14.3)                          0.03               3.9 (1.91-7.93)                0.20† 
DD2 >500ng/mL      5.3 (1.80-13.9)                             0.004              3.45 (0.76-9.40)               0.17† 
           
(*) Analysed on the log scale (base 10) OR, odds ratio; CI, confidence interval; BMI, body mass index; DD1, D-dimer (baseline)  
time 1; DD2, D-dimer (week 2) time 2; NIHSS, national institute of health stroke scale; (*) per 10 year increase in age; (**) per 
10mg/kg 2 increase in BMI;(***) per 4 unit decrease in Barthel index; (****) per 4 unit  increase in NIHSS; (†) adjusted for age, 
NIHSS, BMI, barthel index; Log, logarithm 
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 Discussion 
In this study, the incidence of DVT remained high (19.6%) despite specialist care 
input and a significant proportion of patients receiving thrombolytic therapy. This 
contrasts with clinical experience on the association between good practices regarding 
specialist stroke care reduce incidence of DVT. Amongst participants receiving 
thrombolytic therapy, 21% had DVT and this constitute 40% of DVT in the ischaemic 
stroke group. The incidence of DVT in our patient population  may be partially 
attributable to the existing guidelines in the United Kingdom, which do not support 
the use of pharmacological prophylaxis in acute stroke patients and theoretical risks of 
haemorrhagic transformation of infarct and probable extension of an intracerebral 
haematoma.  Secondly, this incidence can also partly be explained by development of 
DVT prior to demonstration of neurological recovery and early mobilisation, 
considering most patients were mobilised 24 hours after thrombolytic therapy.  
Immobility due to motor limb weakness is a major risk factor for VTE (25-27), and  
development of thrombus in deep veins may have commenced as early as 48 hours 
following stroke (3, 4).  In support of this we confirmed that DVT was associated 
with measures of impairment and disability after acute stroke.  More patients with 
DVT had significant motor limb weakness, significant functional inability, with lower 
Barthel index, and greater  stroke severity score with higher NIHSS.  Thirdly,  lack of 
protection against DVT in patients offered thrombolyic therapy may be due to short 
half life of r-tPA, it also suggest that early DVT prophylaxis in addition to the overall 
hyperacute stroke care is required.  In previous studies, raised serum urea which can 
be a marker of  dehydration, and other acute inflammatory markers, such as 
fibrinogen and  CRP were associated with DVT (28-31). We did not demonstrate an 
association between DVT and fibrinogen. 
Our study is the first to examine thrombin generation in the aftermath of acute stroke, 
and to demonstrate that D-dimer has potential   clinical utility in suggesting at risk 
patients after acute stroke. We theorised that an increase in thrombin generation may 
indicate a predisposition to thrombus formation in the aftermath of acute stroke (32, 
33), and therefore predict those patients that will eventually develop DVT.   However, 
no association was found between thrombin generation and DVT.  The lack of a link 
with thrombin generation, suggests that factors other than a generalised  
prothrombotic tendency determines the development of  DVT after acute stroke.  We 
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confirmed previous findings, that 2-point D-dimer values were significantly 
associated with DVT.  D-dimer assay around day 9 has been shown to have good 
discriminatory power for predicting proximal DVT after acute ischaemic stroke (34).  
Harvey et al in a similar study (n=105) showed D-dimer assay within 24 hours of 
stroke, at cut point of 1591 ng/mL, gives 79% sensitivity, 78% specificity, 35% 
positive predictive value, and 96% negative predictive value (27). We found  D-dimer 
assay within 48 hours of  stroke at a cut-off of 1660 ng/mL had similar clinical utility 
in suggesting underlying DVT burden.  At this cut point, 13/18 (72%) with 
asymptomatic DVT were identified.  Baseline D-dimer is as effective as D-dimer 
measured at later time points in suggesting underlying risk of  DVT, and as a result 
early elevation in D-dimers might be useful in risk stratifying patients need for 
thromboprophylaxis.  D-dimer assay is a readily available, automated, and cheap test, 
in comparison to thrombin generation assay, and could therefore be easily integrated 
into a pretest  assessment model even within the stroke population.  Early initiation of 
pharmacological prophylaxis (within 48 hours) in studies of stroke patients showed 
significant reduction in VTE and with a  non significant increased risk of intracerebral 
haemorrhage after acute ischaemic stroke (35, 36).  Most international guidelines 
recommend pharmacological prophylaxis in immobile and high risk patients, but there 
is no clarity on the time of initiation (14-16, 36).  Inclusion of  D-dimer in future risk 
stratification criteria may assist in identifying those that will benefit  from  early 
detection.  Early detection may further assist in making decisions on prompt initiation 
of thromboprophylaxis, and possibly limit the number needed to treat, and thereby 
reducing the overall risk of bleeding.   Low Barthel index at a cut-off of ≤ 6  should 
raise clinical suspicion,  but not as an independent factor to predict DVT risk as 
previously shown in a study were association with proximal DVT was found at a 
higher cut-off  of ≤ 9  (37).   Ogata et al, previously demonstrated an association 
between DVT and high NIHSS after acute haemorrhagic stroke (11) and at a 
threshold of  ≥ 14, pharmacological prophylaxis was found to be safe and effective 
(36).  At  NIHSS of ≥ 14, 67% of  DVT could have been predicted (67% sensitivity) 
but not as an independent factor.  D-dimer remained the only independent factor with 
good clinical utility to predict DVT.  
Limitations of this study relate to the population investigated, with 48.9% of those 
enrolled completing the follow up, this may not have altered the results on incidence 
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considering that those discharge early were ambulatory within 48 hours and are the 
groups less likely to have developed DVT and were more likely to return for follow 
up.  Due to geographical location of the study centre as a regional hyperacute stroke 
referral centre, early repatriation was unavoidable, and follow up of participants with 
severe stroke in local hospitals was impractical due to differences in local hospital 
specialist input practices and differences in DVT imaging techniques.  Adjustment 
was made for the expected missing data in our analysis.  Application of our findings 
in participants with short hospital stay has limitations.  Given the short duration of  
follow up, and that the  risk of  DVT remains  up to 3 months(38, 39), it is possible  a 
number of later DVT events were missed.  Lastly, due to heterogenous patient 
population and small sample size, we are unable to undertake subgroup analysis in 
relation to stroke subtypes and those that received thrombolytic therapy.   
In conclusion, we have demonstrated that DVT remains a common complication after 
acute stroke, despite thrombolytic therapy and improved specialist stroke care input, 
suggesting a need for additional thromboprophylaxis. In our study population D-
dimer assay was independently associated with DVT, thus suggesting underlying 
DVT risk, when compared to other coagulation assays and measures of stroke 
severity.  Further research to establish the role of D-dimer in identifying acute stroke 
patients at risk of DVT for early thromboprophylaxis is desirable. 
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Highlights 
Clinical and laboratory predictors of DVT (Highlight of key findings) 
 
What we knew 
▪ Subclinical deep vein thrombosis remain a common clinical problem after acute stroke 
▪ Baseline D-dimer within 48 hours of admission best predict post stroke DVT 
▪ Baseline D-dimer ≥1500ng/mL has >70% sensitivity and specificity in the prediction of post stroke 
DVT 
▪ Inclusion of admission D-dimer in DVT prediction model is desirable for future investigations 
 
What is new 
▪ Thrombin generation has no clinical utility in the prediction of post stroke DVT 
▪ Thrombolytic therapy does not protect against post stroke DVT 
 
 
 
